Galinpepimut-S
- Generic Name
- Galinpepimut-S
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 12R66419FZ
- Associated Conditions
- -
- Associated Therapies
- -
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute
SELLAS Life Sciences Group reached the 60-event threshold in its Phase 3 REGAL trial of galinpepimut-S (GPS) for AML, triggering an interim analysis by the Independent Data Monitoring Committee in January 2025. The analysis will assess GPS's efficacy, futility, and safety.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath